FDA Raises No Concerns Over Auxora Safety Data, CalciMedica Advances Trial FDA raises no objections to CalciMedica revised Phase 2 KOURAGE trial, allowing Auxora dosing to resume for acute kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results